Document is current
Any future updates will be listed below
-
Authors
Barger, Carter J. https://orcid.org/0000-0002-1508-0504
Suwala, Abigail K.
Soczek, Katarzyna M.
Wang, Albert S. https://orcid.org/0000-0001-5989-4617
Kim, Min Y.
Hong, Chibo
Doudna, Jennifer A.
Chang, Susan M.
Phillips, Joanna J. https://orcid.org/0000-0002-3789-8120
Solomon, David A. https://orcid.org/0000-0003-4571-7999
Costello, Joseph F. https://orcid.org/0000-0003-3189-584X
-
Funding
Funding for this research was provided by:
NIH
- License Information
-
More Information
Article History
Received: 14 March 2022
Accepted: 1 September 2022
First Online: 16 September 2022
Competing interests
: J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Thera-peutics, Scribe Therapeutics, Synthego, Metagenomi, Mammoth Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and has sponsored research projects by Pfizer, Roche Biopharma, and Biogen. J.F.C. is a co-founder of Telo Therapeutics, Inc. and has ownership interests. The other authors declare no competing interests.
